What happened
Prestige Biologics reported separate results for the fiscal year ended Jun 2026: revenue of US$16.8M (+90% year on year), an operating loss of US$34.7M and a net loss of US$36.4M.
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$16.8M |
|---|---|
| Revenue vs a year earlier | +90% |
| Operating profit | −US$34.7M |
| Net income | −US$36.4M |
| Period | the fiscal year ended Jun 2026 (separate) |
| Filed | 2026-08-14, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260814903378 → open original filing |
Source: DART. Information only, not investment advice.